Open to Enrollment Studies

Hematology & Oncology (Cancer)

FREENOME – The VALLANIA STUDY
A Case-Control Study for the Development of Multiomics Blood Tests for Cancer Screening.  If you are newly diagnosed with any type of cancer, please contact our office.
Principal Investigator: Elise Anderes, MD
Contact Mandy Bartlett, RN, CCRC 406-607-8021 or [email protected]
Or [email protected] - 406-752-7363


MARGIN PROBE 2.0 DATA COLLECTION PROTOCOL
Prospective, single arm, multi-center study, clinical case collection study to acquire Margin Probe data and refine the procedure and algorithm for cancer detection.  For women over 18 years of age diagnosed with cancer and undergoing lumpectomy or partial mastectomy procedure.
Principal investigator: Melissa Kaptanian, MD
Contact:  Mandy Bartlett, RN, CCRC  406-607-8021 or [email protected]
Or [email protected] – 406-752-7636


BREAST CANCER COLLABORATIVE REGISTRY
An investigator-initiated, multisite institutional, non-interventional trial sponsored by the University of Nebraska Medical Center. The registry is focused on the collection of detailed information about participants to help create a resource that will be helpful to researchers in future studies related to breast cancer. It is the hope that future research using information from this registry will lead to improved diagnosis, prevention, and treatment of breast cancers.
Principal investigator: Melissa Kaptanian, MD
Contact:  Mandy Bartlett, RN, CCRC  (406) 607-8021 or [email protected]
Or [email protected]   -   (406) 752-7636


CHIESI CUSA-081-HEM (READY-1) Trial
A Phase 3, Randomized, Double-Blind, Active and Placebo- Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
Principal Investigator, Elise Anderes, MD
Contact: Mandy Bartlett, RN, CCRC  (406) 607-8021 or [email protected]
Or [email protected]   -   (406) 752-7636


MONTANA CANCER CONSORTIUM (NCORP)TRIALS
The Montana Cancer Consortium is an NCI Community Oncology Research Program (NCORP) that gives patients at Logan Health access to more than 80 clinical trials for various disease sites, including brain, breast, lung, gastrointestinal, genitourinary, gynecological, lymphomas, melanoma, multiple myeloma, and neuroendocrine diseases. These trials are sponsored by cooperative groups in the U.S. (i.e., ALLIANCE, ECOG-ACRIN, NRG, SWOG) and the National Cancer Institute (NCI). This includes treatment trials, cancer prevention trials, and cancer care delivery research (CCDR). For more information on the open trials available, visit www.mtcancer.org
Site Principal Investigator, Elise Anderes, MD
Contact: Mandy Bartlett, RN, CCRC  (406) 607-8021 or [email protected]
Or [email protected]   -   (406) 752-7636

 

Cardiology

CARE-HK in HF Registry HQ-NIS-CHF-07.2020
Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalaemia or at High Risk of Hyperkalaemia
Principal investigator: Eve Gillespie, MD, PhD
Contact: [email protected]   -   (406) 752-7636
 
VICTOR HFrEF – MK1242-035
A Pivatol Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults with Chronic Heart Failure With Reduced Ejection Fraction
Principal Investigator: Eve Gillespie, MD, PhD
Contact: [email protected]   -   (406) 752-7636

UPCOMING:
HERMES-E6018-4915
Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.
Principal Investigator: Eve Gillespie, MD, PhD
Contact: [email protected] – (406) 752-7636


 

Endocrinology

DXSDR006
Qualification of a New Fundus Camera Paired with An Autonomous AI for Detecting Diabetic Retinopathy
Principal Investigator: Jose de Souza, MD
Contact: [email protected] - (406) 607-8017
 
Upcoming:
J2A-MC-GZGS – Achieve-4
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
Principal Investigator: Alison Schneider, MD
Contact: [email protected] - (406) 607-8017

Gastroenterology

Contact: [email protected] - (406) 752-7636 for ongoing or upcoming clinical trials


 

Rheumatology

INSPIRE 1 – TILD-19-07
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Site Principal Investigator: Roger Diegel, MD
Contact: Jaime Wyatt, CCRC (406) 755-1460 or [email protected]
Or [email protected]   -   (406) 752-7636
 
 
APEX PSA – CNTO1959PSA3004
 A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutanuously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthristis. APEX
Site Principal Investigator: Roger Diegel, MD
Contact: Jaime Wyatt, CCRC (406) 755-1460 or [email protected]
Or [email protected]   -   (406) 752-7636

Upcoming:
ACELYRIN – 22104
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis.
Site Principal Investigator: Roger Diegel, MD
Contact: Jaime Wyatt, CCRC (406) 755-1460 or [email protected]
Or [email protected] – (406) 752-7636